Abstract:BackgroundGastric cancer (GC) remains a common disease with a poor prognosis worldwide. The SET binding protein 1 (SETBP1) has been implicated in the pathogenesis of several cancers and plays a dual role as an oncogene and a tumor suppressor gene. However, the role and underlying mechanism of SETBP1 in GC remain unclear.Materials and MethodsWe used next-generation RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) to explore the correlation between SETBP1 expression and tumor progression. We then quantified SETBP1 expression in GC cells with real-time quantitative polymerase chain reactions (RT-qPCR). The chi-square test and logistic regression were used to assess the correlation between SETBP1 expression and clinicopathological features. Kaplan-Meier survival analysis and Cox proportional hazards regression model were used to assess the relationship between SETBP1 expression and survival. Finally, gene set enrichment analyses (GSEA) were used to examine GC-related signaling pathways in low and high SETBP1 expressing samples.ResultsWe found SETBP1 expression levels in GC tissues to be significantly lower than in adjacent non-tumor tissues in the TCGA database. In addition, SETBP1 expression differed significantly between groups classified by tumor differentiation. Furthermore, SETBP1 expression in diffuse-type GC was significantly higher than in intestinal-type GC. However, it did not differ significantly across pathological- or T-stage groups. RT-qPCR and comprehensive meta-analysis showed that SETBP1 expression is downregulated in GC cells and tissues. Interestingly, SETBP1 expression in poorly- or un-differentiated GC cells was higher than in well-differentiated GC cells. Moreover, the chi-square test and logistic regression analyses showed that SETBP1 expression correlates significantly with tumor differentiation. Kaplan–Meier curves indicated that patients with relatively high SETBP1 expression had a poor prognosis. Multivariate analyses indicated that SETBP1 expression might be an important predictor of poor overall survival in GC patients. GSEA indicated that 20 signaling pathways were significantly enriched in samples with high and low SETBP1 expression.ConclusionSETBP1 may play a dual role in GC progression.

The Set Gene is a Potential Oncogene in Human Colorectal Adenocarcinoma and Oral Squamous Cell Carcinoma

Expression of set gene in colorectal adenocarcinoma

Cmar_a_255930 4735..4745

[Expression Level of SET Gene in Acute Myeloid Leukemia and Its Clinical Significance].

Involvement of Set in the Wnt Signaling Pathway and the Development of Human Colorectal Cancer

Suppression of cellular apoptosis susceptibility (CSE1L) inhibits proliferation and induces apoptosis in colorectal cancer cells.

The Role of C2orf68 and PI3K/Akt/mTOR Pathway in Human Colorectal Cancer

SET Nuclear Proto-Oncogene Gene Expression is Associated with Microsatellite Instability in Human Colorectal Cancer Identified by Co-Expression Analysis.

Cyclin-dependent Kinase 1-Mediated Phosphorylation of SET at Serine 7 is Essential for Its Oncogenic Activity

Histone Methyltransferase SETDB1 Promotes Colorectal Cancer Proliferation Through the STAT1-CCND1/CDK6 Axis.

Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.

Construction of Set Overexpression Vector and Its Effects on the Proliferation and Apoptosis of 293t Cells

The Role of SETBP1 in Gastric Cancer: Friend or Foe

Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer

SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression

Setdb1 Accelerates Tumourigenesis by Regulating the Wnt Signalling Pathway

Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.

SE translation mRNA overexpression: a potential prognostic predictor in breast cancer

Histone Methyltransferase SETD2 Modulates Alternative Splicing to Inhibit Intestinal Tumorigenesis.

Silencing of SETD6 inhibits the tumorigenesis of oral squamous cell carcinoma by inhibiting methylation of PAK4 and RelA

Histone Methyltransferase SETD2: a Potential Tumor Suppressor in Solid Cancers